<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title> The economics of the public option: Evidence from local pharmaceutical markets</title>
  </titleInfo>
  <name type="personal">
    <namePart>Atal, Juan Pablo et al</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <originInfo>
    <place>
      <placeTerm type="text">The American Economic Review</placeTerm>
    </place>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <form authority="marcform">print</form>
    <extent>114(3), Mar, 2024: p.615-644</extent>
  </physicalDescription>
  <abstract>We study the effects of competition by state-owned firms, leveraging the decentralized entry of public pharmacies to local markets in Chile. Public pharmacies sell the same drugs at a third of private pharmacy prices, because of stronger upstream bargaining and market power in the private sector, but are of lower quality. Public pharmacies induced market segmentation and price increases in the private sector, which benefited the switchers to the public option but harmed the stayers. The countrywide entry of public pharmacies would reduce yearly consumer drug expenditure by 1.6 percent.- Reproduced 

https://www.aeaweb.org/articles?id=10.1257/aer.20211547
</abstract>
  <relatedItem type="host">
    <name>
      <namePart>The American Economic Review  </namePart>
    </name>
  </relatedItem>
  <recordInfo>
    <recordCreationDate encoding="marc">240426</recordCreationDate>
  </recordInfo>
</mods>
